Adamax / Adalank

What Is Adamax / Adalank?

This product combines two separately marketed, adamantane-modified peptide variants into one nasal spray: Adamax, based on Semax, and Adalank, based on Selank. Semax and Selank are both genuine Russian-developed peptides with real clinical histories and are approved as prescription medications in Russia. The adamantane modification applied to each is marketed as improving stability and nasal absorption, a plausible general chemistry principle that has not been tested in published research for either peptide specifically. Combining the two modified variants into a single spray is a vendor formulation decision, not something reflected in the scientific literature.

What Semax is Being Researched For

• Stroke Recovery

  A clinical and electrophysiological study found that adding Semax to standard treatment in the acute period of ischemic stroke was associated with measurable differences in neurological recovery, tracked using clinical rating scales alongside EEG and evoked-potential recordings.^[1]

• Brain-Derived Neurotrophic Factor (BDNF) Production

  Separate mechanistic research found Semax binds specifically to sites tied to BDNF and increases its levels in the rat basal forebrain, a brain region involved in memory and attention, without triggering the cortisol-releasing activity of full-length ACTH.^[2]

• Longer-Term Stroke Rehabilitation

  A follow-up clinical study tracked Semax across both the acute and recovery phases of ischemic stroke, examining motor function, daily living measures, and plasma BDNF over several months rather than just the initial treatment window.

What Selank is Being Researched For

• Generalized Anxiety Disorder

  A Russian clinical trial compared Selank directly against a standard anxiolytic medication in patients with generalized anxiety disorder and neurasthenia, finding comparable reductions in anxiety symptoms along with additional benefits on fatigue that the comparator drug did not produce.^[3]

• Enkephalin Preservation

  Foundational mechanistic research found Selank inhibits the specific enzymes responsible for breaking down enkephalins, the body's own opioid-like signaling molecules involved in mood regulation, proposed as a distinct route to its calming effect.^[4]

• Effects Across Multiple Neurotransmitter Systems

  Broader review research has found Selank's anxiolytic activity isn't limited to enkephalin preservation alone, also touching GABA, serotonin, and dopamine signaling, suggesting its calming effect comes from influencing several systems together rather than one single target.

What's Missing: Data on the Modified, Combined Product

No dedicated research on the adamantane modification of either peptide, and no research at all on combining Semax and Selank together in this specific nasal spray format, was identified anywhere in the published literature. This is distinct from the genuine research behind the underlying, unmodified peptides described above, and it's the single most important gap to understand before drawing conclusions about this specific product.

How Adamax / Adalank Is Marketed as Working

• Semax's Proposed Role

  Research points to Semax increasing BDNF levels in the brain without triggering cortisol release, the proposed basis for its neuroprotective research, a mechanism that would apply to the Adamax component if the modification preserves the parent peptide's activity.^[2]

• Selank's Proposed Role

  Research points to Selank slowing enkephalin breakdown and influencing GABA, serotonin, and dopamine systems, the proposed basis for its calming, anxiolytic research, a mechanism that would apply to the Adalank component under the same assumption.^[3][4]

• An Unverified Modification and Delivery Format

  The adamantane group is marketed as improving stability and nasal absorption for both peptides, and the nasal spray format itself is a legitimate administration route studied for unmodified Semax and Selank individually. Neither the specific modification nor this combined delivery format has been directly tested in published research.

Reconstitution and Handling

Adamax/Adalank is sold as a nasal spray, pre-formulated for intranasal administration rather than requiring reconstitution from a lyophilized powder. The product should be stored according to its specific labeling, generally refrigerated and protected from light.

Key Takeaways

Adamax/Adalank combines two vendor-modified peptide variants, each already missing dedicated research of its own, into a single nasal spray with no additional research behind the combination itself. The genuine evidence that exists belongs to unmodified Semax and Selank individually: Semax's stroke recovery and BDNF research, and Selank's anxiety trial and enkephalin research. Anyone researching this specific product should keep that distinction clear rather than assuming Semax and Selank's research transfers automatically to this modified, combined form.

Frequently Asked Questions

Sources and Research

1. Gusev EI, Skvortsova VI, Miasoedov NF, et al. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26-34.
2. Dolotov OV, Karpenko EA, Seredenina TS, et al. Semax, an analogue of adrenocorticotropin(4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006;97(Suppl 1):82-86.
3. Zozulya AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48.
4. Zozulya AA, Kost NV, Sokolov OY, et al. The Inhibitory Effect of Selank on Enkephalin-Degrading Enzymes as a Possible Mechanism of Its Anxiolytic Activity. Bull Exp Biol Med. 2001;131(4):315-317.